免疫チェックポイント阻害剤の米国食品医薬品局承認における免疫関連の有害事象の報告
Shaili Tapiavala1, Chongliang Luo2, Mina Shenouda3
1Division of Oncology, Washington University in St. Louis, St. Louis, MO, United States.
Frontiers in oncology
|August 29, 2025
まとめ
免疫チェックポイント阻害剤 (ICI) の臨床試験における免疫関連の有害事象 (irAEs) の報告は,特に希少な事象では一貫していない. ICIの毒性を明確に伝えるためには,報告の標準化が不可欠です.
科学分野:
- 腫瘍学
- 臨床試験
- 免疫療法
背景:
- 免疫チェックポイント阻害剤 (ICI) は,免疫関連の有害事象 (irAEs) を引き起こします.
- 発症率と生活の質への影響が大きいため,IRAEのモニタリングは不可欠です.
- IREの予測と報告は複雑です
研究 の 目的:
- 報告パターンとIREの一貫性を体系的に評価する.
- 米国FDAのICI承認に至る試験におけるIRAE報告を分析する.
主な方法:
- 2011年から2021年までの75の主要な記事をレビューした.
- 24件のIREの発生頻度とその報告状況について収集したデータ
- 研究年,段階,腫瘍型,治療型による傾向を分析した.
主要な成果:
- irAEの報告に重大な矛盾が認められた.
- 腹/腸炎 (100%),疲労 (99%),発疹 (93%) が最も多く報告されました.
- 筋膜炎 (21%),ウエビチス (17%),無菌性髄膜炎 (4%) がまれに報告されました.
- より稀なIRAの報告は,時間とともに増加した.
結論:
- 主要な文献では,IRAEの報告に重大な矛盾があることが示されています.
- 臨床試験から発現したIRAEの標準化報告が必要である.
- 報告の改善により,ICIの毒性に関する情報の普及が促進されます.
さらに関連する動画
05:21Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
469
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
8.8K
関連する概念動画
Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Allergic Drug Reactions
972
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
972
